Logo image of LEXX

LEXARIA BIOSCIENCE CORP (LEXX) Stock Fundamental Analysis

NASDAQ:LEXX - Nasdaq - US52886N4060 - Common Stock - Currency: USD

0.97  +0.01 (+1.04%)

After market: 0.9894 +0.02 (+2%)

Fundamental Rating

3

LEXX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. The financial health of LEXX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LEXX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LEXX has reported negative net income.
LEXX had a negative operating cash flow in the past year.
LEXX had negative earnings in each of the past 5 years.
In the past 5 years LEXX always reported negative operating cash flow.
LEXX Yearly Net Income VS EBIT VS OCF VS FCFLEXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

LEXX has a Return On Assets of -108.13%. This is in the lower half of the industry: LEXX underperforms 76.26% of its industry peers.
LEXX has a Return On Equity of -131.33%. This is in the lower half of the industry: LEXX underperforms 62.63% of its industry peers.
Industry RankSector Rank
ROA -108.13%
ROE -131.33%
ROIC N/A
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
LEXX Yearly ROA, ROE, ROICLEXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 99.49%, LEXX belongs to the top of the industry, outperforming 98.48% of the companies in the same industry.
In the last couple of years the Gross Margin of LEXX has grown nicely.
The Profit Margin and Operating Margin are not available for LEXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
LEXX Yearly Profit, Operating, Gross MarginsLEXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LEXX has been increased compared to 1 year ago.
The number of shares outstanding for LEXX has been increased compared to 5 years ago.
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LEXX Yearly Shares OutstandingLEXX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
LEXX Yearly Total Debt VS Total AssetsLEXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -4.57, we must say that LEXX is in the distress zone and has some risk of bankruptcy.
LEXX has a worse Altman-Z score (-4.57) than 61.11% of its industry peers.
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACC8.49%
LEXX Yearly LT Debt VS Equity VS FCFLEXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 4.24 indicates that LEXX has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.24, LEXX is doing good in the industry, outperforming 67.68% of the companies in the same industry.
A Quick Ratio of 4.24 indicates that LEXX has no problem at all paying its short term obligations.
The Quick ratio of LEXX (4.24) is better than 68.18% of its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
LEXX Yearly Current Assets VS Current LiabilitesLEXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

LEXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.71%, which is quite good.
LEXX shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.14%.
Measured over the past years, LEXX shows a quite strong growth in Revenue. The Revenue has been growing by 16.11% on average per year.
EPS 1Y (TTM)14.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
Revenue 1Y (TTM)36.14%
Revenue growth 3Y-13.6%
Revenue growth 5Y16.11%
Sales Q2Q%20%

3.2 Future

Based on estimates for the next years, LEXX will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.78% on average per year.
LEXX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 181.98% yearly.
EPS Next Y-36.74%
EPS Next 2Y-8.75%
EPS Next 3Y-19.78%
EPS Next 5YN/A
Revenue Next Year16.34%
Revenue Next 2Y15.26%
Revenue Next 3Y21.24%
Revenue Next 5Y181.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LEXX Yearly Revenue VS EstimatesLEXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 50M 100M 150M 200M
LEXX Yearly EPS VS EstimatesLEXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LEXX Price Earnings VS Forward Price EarningsLEXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEXX Per share dataLEXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as LEXX's earnings are expected to decrease with -19.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.75%
EPS Next 3Y-19.78%

More info and screens

0

5. Dividend

5.1 Amount

LEXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (5/22/2025, 8:20:21 PM)

After market: 0.9894 +0.02 (+2%)

0.97

+0.01 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-14 2025-04-14/dmh
Earnings (Next)07-10 2025-07-10
Inst Owners8.04%
Inst Owner Change-12.69%
Ins Owners7.81%
Ins Owner Change31.41%
Market Cap18.90M
Analysts82.86
Price Target7.14 (636.08%)
Short Float %3.25%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.8%
Min EPS beat(2)-30.72%
Max EPS beat(2)5.12%
EPS beat(4)1
Avg EPS beat(4)-18.43%
Min EPS beat(4)-30.72%
Max EPS beat(4)5.12%
EPS beat(8)3
Avg EPS beat(8)-10.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)52.42%
Min Revenue beat(2)24.52%
Max Revenue beat(2)80.31%
Revenue beat(4)2
Avg Revenue beat(4)1.7%
Min Revenue beat(4)-52.94%
Max Revenue beat(4)80.31%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-22.22%
EPS NQ rev (1m)-8.05%
EPS NQ rev (3m)-8.05%
EPS NY rev (1m)-5.41%
EPS NY rev (3m)-12.12%
Revenue NQ rev (1m)-33.34%
Revenue NQ rev (3m)-33.34%
Revenue NY rev (1m)-23.03%
Revenue NY rev (3m)-23.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.93
P/FCF N/A
P/OCF N/A
P/B 2.64
P/tB 2.85
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.03
BVpS0.37
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.13%
ROE -131.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.49%
FCFM N/A
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 234.78%
Cap/Sales 29.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -4.57
F-Score3
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)180.28%
Cap/Depr(5y)128.17%
Cap/Sales(3y)61.25%
Cap/Sales(5y)40.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
EPS Next Y-36.74%
EPS Next 2Y-8.75%
EPS Next 3Y-19.78%
EPS Next 5YN/A
Revenue 1Y (TTM)36.14%
Revenue growth 3Y-13.6%
Revenue growth 5Y16.11%
Sales Q2Q%20%
Revenue Next Year16.34%
Revenue Next 2Y15.26%
Revenue Next 3Y21.24%
Revenue Next 5Y181.98%
EBIT growth 1Y-72.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.34%
OCF growth 3YN/A
OCF growth 5YN/A